Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could blocking GLP-1 restore the Body's natural defense against low blood sugar?

NCT ID NCT07373236

Knowledge-focused Sponsor: Asger Lund, MD Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study looked at why people with type 1 diabetes lose their natural defense against low blood sugar—the hormone glucagon. Researchers tested whether blocking a hormone called GLP-1 with a drug (exendin(9-39)amide) could restore glucagon release during low blood sugar. Twelve adults with type 1 diabetes took part, receiving either the blocker or a placebo. The goal was to see if this mechanism works in humans, which could lead to new treatments to reduce hypoglycemia risk.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
exendin(9-39)amide (a GLP-1 blocker)
What this could lead to
If successful, this could point toward a new add-on treatment to insulin therapy that lowers the risk of dangerously low blood sugar in type 1 diabetes.
What could go wrong
This is a very small, early-stage study (12 people) testing a mechanism, not a treatment. Results may not lead to a usable therapy, and the blocker itself may have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

12 people

The number who actually took part.

Started

Jan 2026

Finished

Apr 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Caucasian ethnicity * Age between 18 and 70 years * T1D (diagnosed according to the criteria of the World Health Organization) with HbA1c \<69 mmol/mol (\<8.5%) * Body mass index between 19 and 30 kg/m2 * T1D duration of 2-30 years * C-peptide negative (5 gram arginine-stimulated C-peptide ≤100 pmol/l) * Treatment with a stable basal-bolus or insulin pump regimen for ≥3 months Exclusion Criteria: * Anaemia (haemoglobin below normal range) * Late microvascular complications except mild non-proliferative retinopathy * Liver disease (Evaluated by alanine aminotransferase (ALAT) and/or aspartate aminotransferase (ASAT) \>2 times normal values) or a history of hepatobiliary disorder * Kidney disease (serum creatinine above normal range) * Treatment with any glucose-lowering drugs beside insulin * Active or recent (within 5 years) malignant disease * Regular tobacco smoking or use of other nicotine-containing products * Any condition considered incompatible with participation by the investigators.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Type 1 diabetes are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hypoglycemia type 1 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Type 1 diabetes

Contacts and locations

Locations

  • Gentofte Hospital

    Hellerup, 2100, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.